ArticleBMC psychiatry2026
Assessment of oxidative stress markers in multi-episode schizophrenia: a comparative study before and after electroconvulsive therapy and their correlation with clinical improvement.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study examined oxidative stress (OS) markers in acute relapse schizophrenia, assessed the impact of electroconvulsive therapy (ECT), and explored correlations with clinical improvement.
methods110 Han Chinese patients and 55 healthy controls were enrolled. All enrolled patients had multi-episode schizophrenia with a mean illness duration of 11.15 ± 9.11 years. Patients received 8-12 bilateral ECT sessions plus antipsychotics. Serum levels of GSH-Px, MnSOD, CuZnSOD, and CAT were measured before and after ECT. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS).
resultsAt baseline, schizophrenia patients showed significantly lower serum levels of GSH-Px, MnSOD, and CAT, while the MnSOD/CuZnSOD ratio was decreased, CuZnSOD levels showed a non‑significant trend as compared to healthy controls. GSH-Px levels were negatively correlated with the PANSS positive subscale scores (p = 0.007). Following ECT, all PANSS scores significantly decreased (all p < 0.001). Serum levels of GSH-Px, TSOD, CuZnSOD, and CAT increased significantly, while MnSOD levels and the MnSOD/CuZnSOD ratio significantly decreased (all p < 0.01). In responders, changes to OS markers were significant (all p < 0.01). Increases in GSH-Px levels were positively correlated to reductions in the PANSS total score (Bonferroni corrected p = 0.024) and general subscale scores (Bonferroni corrected p = 0.008). Multivariate logistic regression analysis identified the baseline GSH-Px level as an independent potential indicator of clinical improvement (p = 0.001).
conclusionAcute relapse schizophrenia shows significant redox imbalance. ECT in combination with antipsychotics modulates antioxidant enzymes, and GSH-Px dynamics correlate with symptom improvement, suggesting its potential as a predictive and monitoring biomarker for ECT outcomes. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.